Moderna's Madrid Moment: Cancer Data Takes Center Stage as Shares Extend Historic Run
Published on 09/22/2026 at 06:42 | Editorial boerse-global.de
Moderna shares jumped 13% on Monday, closing at EUR 150.76, after the biotech confirmed that abstracts from the Phase 3 trial of its personalized cancer vaccine Intismeran Autogene were accepted for the Presidential Symposium at the upcoming ESMO 2026 congress in Madrid. The designation is widely read in oncology circles as a signal that the data could be practice-changing.
The stock now trades just 2.1% below its 52-week high of EUR 154.00. The move extends a remarkable run: since the start of the year, the shares have gained 468%, a surge that reflects enormous expectations for the company's oncology pipeline.
A Prominent Stage on October 24
Madrid will give Moderna a high-profile platform on October 24 to present detailed analyses from the Phase 3 study. The abstract acceptance follows a separate catalyst roughly a week earlier, when the company's announcement of Phase 3 results sparked an 18.7% single-day gain.
Wolfe Research upgraded the stock to Peerperform, noting that the positive melanoma data had substantially reduced development risk for the platform. The firm pegged peak sales potential at USD 9.2 billion.
The trial in question, INTerpath-001, tests Intismeran Autogene in combination with Merck's antibody Pembrolizumab in patients with resected high-risk melanoma. Interim results have painted a favorable picture. Whether that statistical advantage justifies the lofty valuation remains a matter of debate among experts — only the full survival curves will reveal the true magnitude and durability of the benefit.
Should investors sell immediately? Or is it worth buying Moderna?
Beyond Melanoma: A Pipeline With Broader Ambitions
A simple survival edge is unlikely to sustain a re-rating. The therapy must effectively prevent relapse over years to justify the considerable logistical burden of patient-specific tumor sequencing. If the data meet those demanding criteria, Moderna could secure a dominant position in a new therapeutic category, with broad acceptance from regulators and oncologists alike.
The approach targets far more than melanoma. At the Madrid conference, management plans to present additional data on pancreatic and lung cancer. Market watchers see peak sales for the Intismeran program reaching the high single-digit billions across multiple indications. A clinical triumph would fundamentally transform the business model, reducing reliance on the seasonal vaccine market while shoring up the value of the broader development pipeline.
A Vaccine Business Still Pulling Its Weight
While oncology commands the spotlight, Moderna continues to advance its traditional vaccine franchise. On August 27, the FDA granted approval for Spikevax and mNEXSPIKE. The updated COVID-19 vaccines for the 2026–2027 season target the XFG subvariant of the JN.1 lineage and are cleared for at-risk patients aged six months to 64 years, as well as all individuals 65 and older. The authorization provides a predictable base of revenue for the company.
Valuation Skepticism Creeps In
Not everyone is cheering the rally. Rothschild & Co downgraded the stock to Sell from Neutral on September 3, even as it raised its price target to USD 81 from USD 40, citing operational developments. The split verdict underscores a broader tension: the fundamental earnings picture still warrants caution, with operations continuing to burn through cash at a rapid clip. Should market readiness be delayed, the company could remain loss-making for years.
The downside risk has grown in tandem with the share price. If the protective effect fades over time, a sharp disillusionment could follow. The valuation already embeds substantial advance praise, and mediocre detailed data would also raise doubts about the commercial scalability of individualized mRNA manufacturing.
Madrid as the Decisive Fork in the Road
As long as the market trusts in a convincing trial outcome, the uptrend can hold. Should confidence in the efficacy data waver, a sharp correction looms — the valuation leaves no room for scientific ambiguity. Media reports suggest market participants are now focused squarely on the detailed medical analyses to be presented at the Madrid conference in late October. A conference call for institutional investors will follow immediately after the presentation, marking the pivotal event for the stock's medium-term direction.
Ad
Moderna Stock: New Analysis - 22 September
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
